Sexual and reproductive health care.

The measure, led by Assembly Member Aguiar-Curry with Assembly Member Patel as the principal coauthor and a broad coalition of collaborators, is aimed at preserving steady access to medication abortion in California amid shifting federal policy while recalibrating professional and health-plan regulation around reproductive-health services. It advances a core shift by repealing provisions that were identified as unconstitutional restrictions related to abortion access for incarcerated individuals and committed juveniles, and by removing obsolete references to criminal abortion penalties. The proposal also frames the act as an urgency measure to take effect immediately, signaling the intent to ensure uninterrupted access in a climate of uncertainty at the federal level.

Key mechanisms include a comprehensive set of changes to how mifepristone and other medications used in abortion care are regulated, dispensed, and covered. The measure would authorize the state public-health department to determine whether mifepristone and related drugs should be included in or excluded from the Sherman labeling regime, with the option to exclude drugs that FDA has ceased approving. It would permit pharmacists to dispense mifepristone or other abortion drugs without naming the patient, prescriber, or pharmacy under specified conditions, while maintaining a log that is protected from broad law-enforcement access unless subpoenaed and shielded from out-of-state disclosure. The bill provides that certain acts related to these drugs could not be grounds for disciplinary action against pharmacists or healing-arts licensees, and it would prohibit state boards from denying licensure or taking disciplinary action solely for engaging in lawful manufacturing, transport, or distribution activities. It also creates protections for clinics and health facilities and extends certain immunities to health-care providers for off-label use of abortion drugs, subject to defined exceptions for imminent health or safety concerns.

On the insurance, contract, and clinical-regulatory front, the measure requires health-care service plans and insurers to cover brand-name or generic mifepristone even when used off-label, provided specified criteria are met, including medical necessity for life-threatening or chronic, seriously debilitating conditions and recognition in established medical references or guidelines. If FDA approval for abortion is lacking, coverage may be required when the drug is recognized for those indications by major compendia, peer-reviewed evidence, or WHO guidance, among other standards, with an explicit provision that administration-related services must be covered as well. The measure also tightens protections against discrimination in provider contracts and strengthens the obligation of prescribers to supply documentation to insurers when requested. Finally, the bill broadens patient-privacy protections for abortion-related information in civil discovery and health-record disclosures, while still allowing data-sharing under narrowly defined conditions, and it includes severability and other governance provisions to guide implementation.